SLC5A2 and chronic kidney disease: Heerspink HLJ et al. [47] conducted a double-blind, active-controlled, Phase IIb study to evaluate the efficacy and safety of the endothelin A receptor antagonist zibotentan in combination with the SGLT2 inhibitor dapagliflozin in 415 adults with CKD (Zibotentan and Dapagliflozin for the Treatment of CKD; ZENITH-CKD).